Abstract: Provided is a long-acting method for preventing or treating glucose metabolism disorders that includes administering a beta-lactam compound or a pharmaceutically acceptable salt thereof to a subject in need thereof. The method for preventing or treating glucose metabolism disorders has a long-acting effect that lasts more than two days even after medication has been stopped.

Abstract: Provided is a long-acting method for preventing or treating glucose metabolism disorders that includes administering a beta-lactam compound or a pharmaceutically acceptable salt thereof to a subject in need thereof. The method for preventing or treating glucose metabolism disorders has a long-acting effect that lasts more than two days even after medication has been stopped.

Abstract: Provided is a long-acting method for preventing or treating glucose metabolism disorders that includes administering a beta-lactam compound or a pharmaceutically acceptable salt thereof to a subject in need thereof. The method for preventing or treating glucose metabolism disorders has a long-acting effect that lasts more than two days even after medication has been stopped.

Abstract: Provided is a long-acting method for preventing or treating glucose metabolism disorders that includes administering a beta-lactam compound or a pharmaceutically acceptable salt thereof to a subject in need thereof. The method for preventing or treating glucose metabolism disorders has a long-acting effect that lasts more than two days even after medication has been stopped.

Abstract: A control method for surveillance system includes the steps of: detecting a region of interest by an infrared sensor; generating a trigger signal by the infrared sensor when the infrared sensor detects a moving object in the region of interest; receiving the trigger signal by a controller and determining accordingly thereby whether to generate an enable command; taking pictures of the region of interest to generate an image thereof, by an infrared camera, when the infrared camera receives the enable command; receiving the image by the controller and determining accordingly thereby whether the image meets an illumination-related criterion; sending an illumination command by the controller when the image meets the illumination-related criterion; and emitting visible light by a lamp when the lamp receives the illumination command.

Abstract: A display device employing a liquid crystal module and a method for fabricating the display device are provided. The liquid crystal module includes a first substrate and a second substrate, wherein the first substrate is disposed opposite to the second substrate; a first photo-alignment layer disposed on a top surface of the first substrate, and a second photo-alignment layer disposed on a bottom surface of the second substrate, wherein the first and second photo-alignment layers include a plurality of protrusions, and wherein the protrusions are formed by polymerizing non-polar monomers having two or three acrylate functional groups; and a liquid crystal layer disposed between the first and second photo-alignment layers.

Abstract: Disclosed herein are compositions and methods relating to the modulation of Appoptosin levels or activity in the treatment of Neurodegenerative disorders or cancer.

Abstract: Disclosed herein are compositions and methods relating to peptides. The peptides can inhibit amyloid beta (A?) generation and reduce GSK-3 activities. Further provided are compositions and methods for treating or preventing, for example, Alzheimer's disease, cancer, and diabetes.

Abstract: The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine cells indicated that E4B9 indeed cross-reacts with human VE-cadherin (FIG. 6). This finding facilitates development of a “humanized” E4B9 antibody and its success in the preclinical development since its anti-tumor activity can be tested extensively in several mouse models.

Abstract: The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine cells indicated that E4B9 indeed cross-reacts with human VE-cadherin (FIG. 6). This finding facilitates development of a “humanized” E4B9 antibody and its success in the preclinical development since its anti-tumor activity can be tested extensively in several mouse models.

Abstract: The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine cells indicated that E4B9 indeed cross-reacts with human VE-cadherin. (FIG. 6). This finding facilitates development of a “humanized” E4B9 antibody and its success in the preclinical development since its anti-tumor activity can be tested extensively in several mouse models.

Abstract: The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VIE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine ceH indicated that E4B9 indeed cross-reacts with human VE-cadherin (FIG. 6). This finding facilitates development of a “humanized” E4B9 antibody and its success in the prectinical development since its anti-tumor activity can be tested extensively in several mouse models.

Abstract: Disclosed herein are compositions and methods relating to the modulation of Appoptosin levels or activity in the treatment of Neurodegenerative disorders or cancer.

Abstract: Display devices with light shading ability are provided. An exemplary embodiment of a display device with light shading ability includes a housing, a display unit, and a light shade. The display unit is disposed in the housing. The light-shading assembly is detachably disposed on the housing by a magnetic force. Thus, the display unit is shielded from partial illumination by environmental light.

Abstract: A breathing shoe is disclosed to include an air pumping mechanism formed of an air bladder and mounted in the top wall of the outsole for pumping outside cooling air into a front part inside the shoe body to force foul air out of the shoe body through air holes in the front upper part of the shoe body when the user is walking or running.

Abstract: The present invention is directed to methods utilizing vascular endothelial growth factor receptor (VEGFR) antagonists to treat atherosclerosis and other inflammatory diseases.

Abstract: The present invention includes the use of an antagonist of vascular endothelial growth factor receptor (VEGFR) in combination with an antagonist of vascular endothelial cadherin (VE-cadherin) to modulate angiogenesis. Included is the use of the VEGFR antagonist and the antagonist of VE-cadherin in a manner so as to prevent or ameliorate toxicity associated with the use of VE-cadherin antagonist. The present invention also comprises the use of a VEGFR antagonist and a VE-cadherin antagonist for treating, with reduced toxicity, diseases associated with angiogenesis, which include but are not limited to neoplastic diseases, autoimmune diseases and collagen vascular diseases, as well as the use of a VEGFR antagonist for the treatment of disease states associated with pathological vascular permeability which include, but are not limited to, ARDS, edema states and related conditions.

Abstract: The susceptibility to human immunodeficiency virus (HIV) infection depends on the cell surface expression of the human CD4 molecule and a human fusion accessory factor associated with HIV infection (STRL33). STRL33 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. STRL33 plays a role in the membrane fusion step of HIV infection for both TCL-tropic and M-tropic variants of HIV. The invention provides STRL33 polypeptide and polynucleotide sequences encoding STRL33 polypeptide. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and STRL33 provides valuable tools for the continuing research of HIV infection and the development of more effective anti-HIV therapeutics. In addition, antibodies against STRL33, isolated and purified peptide fragments of STRL33, and STRL33-binding biologic agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics.

Abstract: This invention relates to antibodies, or immunologically active fragments thereof, specific for the N-terminal 15 amino acids of a mammalian VE-cadherin and which act as antagonists of VE-cadherin-mediated homophilic interactions between adjacent endothelial cells without adversely affecting normal vasculature. In a preferred embodiment, the antibodies are humanized antibodies directed that react with human VE-cadherin for use in a human. The invention also provides pharmaceutical compositions comprising these antibodies and antibody fragments, methods of preparing the antibodies, and methods of using the antibodies and antibody fragments to inhibit angiogenesis, inhibit tumor metastasis, or treat cell proliferative disorders.

Abstract: A joint engagement device includes a base board having a plurality of first joints defined therein and two sidewalls extend from the base board. A connection board is connected between the two sidewalls and two slots are defined through the connection board so that two posts of a carrier member movbaly extend therein. An operation frame has two arms each of which is connected between the sidewall and the post. An engaging board has a plurality of second joints and is engaged with between the two posts of the carrier member. The carrier member carries the engaging board to move toward the base board to engage the second joints with the first joints when pivoting the operation frame toward the base board.